BETAPLUS PHARMA

Active

Public limited companyfounded 200223 yrs activeHippokrateslaan 10, 1200 Sint-Lambrechts-Woluwe, BelgiumKBO/BCE: BE 0479.037.369

Summary

BETAPLUS PHARMA has been active since 2002 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €22.3m and a net result of €1.3m. Equity is growing by ~7.6% per year across the filed fiscal years. Its solvency ranks better than 88% of 65 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.5% (very low).

Risk analysis Watch Report Compare

BETAPLUS PHARMAActiveChecked score 79/100

Risk analysis Report Compare

Checked score

Score 2025

79 / 100

Excellent

Every signal that weighs is under Signals.

Axes · tick = 2024

Profitability83▼-2

Solvency100=

Growth44=

Track record100

Bankruptcy probability, 12 months

0.5% Very low

0%0.5%1.5%4%10%≥ 25%

Credit up to €500,000 at 30 days acceptable

Liquidity ample (current ratio 24.55 against 22.08 in 2024; short-term debt: 3.9% and cash: 0.1% of total assets), and 10.2% of the assets are financed with debt.

Credit check for your own amount and term

Open the credit simulator : see how the verdict changes with amount, term and advance.

Signals

Six signals. The signal on the left, the evidence on the right.

−lowers risk+raises risk○neutral

Higher-failure-rate region

In this region companies fail more often than in the rest of the country.

KBO · registered office

Annual accounts: healthy financial profile

The latest annual accounts show a healthy profile in solvency, result and liquidity.

NBB · annual accounts 2025

Solvency, return and age of the figures

Solvency

89.8%

Return on assets

5.1%

Age of the figures

9 mo

Long track record

A company with a long track record statistically fails less often than a young one.

KBO · incorporation date

Age against the risk zone

Lower-risk legal form

Companies with this legal form statistically fail less often than a BV.

KBO · legal form

Higher-failure-rate sector

In this sector companies fail more often than the Belgian average.

Gazette · bankruptcies per sector, NACE 21

Relative position

BE, all sectors

reference

Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)

about 14% more bankruptcies

← fewer bankruptcies more bankruptcies →

Filed after the deadline

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 03-08-2026, 3 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.

NBB · 10 filings

Deviation from the deadline

2025

3 d late

2024

15 d early

2023

29 d early

2022

21 d late

2021

107 d late

2020

45 d early

2019

4 d late

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 7 days after the deadline; the sector median for financial year 2024 is 9 days before the deadline, and 32% of the sector filed late.

Checked, nothing found (2)

The next deadline is still running

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.

Companies Code · seven months

Position in the running window

27-09-2026 today31-12-2026 close31-07-2027 deadline

No strike-offs in the KBO publications

We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

KBO publications · our coverage

History

On 16 December 2002, BETAPLUS PHARMA was incorporated.¹ Of the 5 current board members, Philippe DEHASPE has served longest, since 2008.² Revenue went from EUR 6 million in 2018 to EUR 5.4 million in 2025 and headcount from 10.5 to 11.3 full-time equivalents.³

Go further with this company

How much credit can you give this customer, and on what term?Credit simulator What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed

Is this your company? See how customers and banks see it.

Investigating this company? Keep it with today's facts in a case file.

Financials · fiscal year 2025, full schema

In the rankings #1 company by equity in Sint-Lambrechts-Woluwe, Manufacturing sector #2 company by total assets in Sint-Lambrechts-Woluwe, Manufacturing sector

Turnover

€5.4m▲ 0.3%

2024 · €5.4m

EBIT margin

23.2%▼ 2.4pp

2024 · 25.6%

Net result

€1.3m▼ 22.6%

2024 · €1.6m

Working capital

€23.1m▲ 5.6%

2024 · €21.8m

Trend over the years

Chart Table

Click a name to add, emphasise or remove a line.

Every figure with its change against the fiscal year before

favourable unfavourable

Line20212022202320242025

Turnover€6.1m▲ 7.0%€5.1m▼ 15.8%€4.5m▼ 11.4%€5.4m▲ 18.6%€5.4m▲ 0.3%

Operating result€2.2m▲ 24.4%€1.5m▼ 33.8%€647,713▼ 56.5%€1.4m▲ 114%€1.3m▼ 9.3%

Net result€1.6m▲ 14.4%€1.2m▼ 22.6%€969,273▼ 21.3%€1.6m▲ 69.5%€1.3m▼ 22.6%

EBIT margin36.8%▲ 5.2pp29.0%▼ 7.9pp14.2%▼ 14.7pp25.6%▲ 11.4pp23.2%▼ 2.4pp

Equity€17.2m▲ 10.2%€18.4m▲ 7.2%€19.4m▲ 5.3%€21.1m▲ 8.5%€22.3m▲ 6.0%

Total assets€19.9m▲ 8.0%€20.8m▲ 4.8%€21.9m▲ 5.1%€23.7m▲ 8.1%€24.9m▲ 5.1%

Debt€1.4m▼ 15.6%€944,351▼ 30.2%€904,697▼ 4.2%€1.0m▲ 14.4%€978,856▼ 5.4%

Working capital€17.6m▲ 11.8%€19.0m▲ 7.4%€20.2m▲ 6.4%€21.8m▲ 8.2%€23.1m▲ 5.6%

Staff (FTE)12.5▲ 7.8%11.5▼ 8.0%11.5=11.5=11.3▼ 1.7%

Why a figure moved sharply

2024 Net result +70% on 2023. Cause not known from the registers.

Result per fiscal year

Operating resultNet result

The operating result falls in 2025; 2025 is 9% below 2024.

Balance-sheet composition

2025 in colour, 2024 as the grey bar beneath

Assets €24.9m

96.6%

Fixed assets €835,211 ▲ 4.9%

Current assets €24.0m ▲ 5.1%

Equity and liabilities €24.9m

89.8%

Equity €22.3m ▲ 6.0%

Provisions €1.6m =

Debt €978,856 ▼ 5.4%

Debt's share of the balance-sheet total falls from 4.4% to 3.9%. Equity is higher and debt is lower.

Key figures and ratios

2025 value · change against 2024

EBITDA

€1.5m▼

2024 · €1.6m

Cash flow

€1.5m▼

2024 · €1.8m

Current ratio

24.55▲

2024 · 22.08

Quick ratio

24.22▲

2024 · 21.83

Debt to equity

0.04▼

2024 · 0.05

ROE

5.7%▼

2024 · 7.8%

ROA

5.1%▼

2024 · 6.9%

Interest coverage

14.64▼

2024 · 17.55

Debt ≤ 1 year

€978,856▼

2024 · €1.0m

Income taxes

€458,608▼

2024 · €507,679

Staff costs

€1.2m▼

2024 · €1.2m

Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Peer companies

Historical observation

Of the 20,082 companies that looked in July 2024 the way this one looks now, 0.2% went bankrupt within 24 months and 95% are still going.

Small
20 years or older
solvency 30% or more
a profit of 5% of the balance sheet or more

0.2% went bankrupt

4.7% stopped otherwise

95% still going

For this company itself Checked computes a bankruptcy probability of 0.5% over twelve months; the group does not contradict it.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,058 companies of July 2024 its group's bankruptcy share. Expected: 1.5%; actually bankrupt within 24 months: 1.6%.

The companies in ten equal groups, from lowest to highest expected share.
Group	Expected	Actual
1	0.2%	0.2%
2	0.3%	0.4%
3	0.5%	0.5%
4	0.6%	0.7%
5	0.8%	0.9%
6	1.2%	1.3%
7	1.5%	1.6%
8	1.7%	1.7%
9	2.7%	2.8%
10	5.3%	5.7%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 20,082 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts

OverviewIncome statement Balance sheet Cash flow

Filed annual accounts As filed with the NBB · 2025 against 2024 · 58 lines

Balance sheet Code20242025

Assets

Total assets20/58€23.7m€24.9m▲

Fixed assets21/28€795,964€835,211▲

Intangible fixed assets21€0€24,929▲

Tangible fixed assets22/27€750,743€767,266▲

Land and buildings22€60,043€95,937▲

Plant, machinery and equipment23€576,016€595,018▲

Furniture and vehicles24€43,815€23,651▼

Leasing and similar rights25-€3,233

Assets under construction and advance payments27€70,869€49,426▼

Financial fixed assets28€45,221€43,017▼

Current assets29/58€22.9m€24.0m▲

Stocks and contracts in progress3€257,920€320,890▲

Stocks30/36€257,920€320,890▲

Amounts receivable within one year40/41€22.5m€23.7m▲

Trade receivables40€613,860€588,367▼

Other amounts receivable41€21.9m€23.1m▲

Cash at bank and in hand54/58€2,481€14,655▲

Deferred charges and accrued income490/1€108,178€17,653▼

Equity and liabilities

Total equity and liabilities10/49€23.7m€24.9m▲

Equity10/15€21.1m€22.3m▲

Contributions10/11€2.4m€2.4m=

Capital10€2.0m€2.0m=

Issued capital100€2.0m€2.0m=

Outside capital11€391,000€391,000=

Share premium1100/10€391,000€391,000=

Reserves13€200,000€200,000=

Non-distributable reserves130/1€200,000€200,000=

Legal reserve130€200,000€200,000=

Profit (loss) carried forward14€18.5m€19.7m▲

Provisions and deferred taxes16€1.6m€1.6m=

Provisions for liabilities and charges160/5€1.6m€1.6m=

Environmental obligations163€1.6m€1.6m=

Amounts payable17/49€1.0m€978,856▼

Amounts payable within one year42/48€1.0m€978,856▼

Trade debts44€679,748€780,733▲

Suppliers440/4€679,748€780,733▲

Taxes, remuneration and social security45€355,460€198,123▼

Taxes450/3€45,881-

Remuneration and social security454/9€309,579€198,123▼

Income statement Code20242025

Turnover70€5.4m€5.4m▲

Goods, raw materials, services and sundry goods60/61€2.5m€2.7m▲

Remuneration, social security and pensions62€1.2m€1.2m▼

Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€204,740€217,122▲

Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4€445-€1,964▼

Other operating charges640/8€15,732€15,398▼

Gross operating margin9900€2.8m€2.7m▼

Operating profit (loss)9901€1.4m€1.3m▼

Financial income75/76B€857,827€575,605▼

Recurring financial income75€857,827€575,605▼

Financial charges65/66B€90,466€100,539▲

Recurring financial charges65€90,466€100,539▲

Profit (loss) for the period before taxes9903€2.2m€1.7m▼

Income taxes67/77€507,679€458,608▼

Profit (loss) for the period9904€1.6m€1.3m▼

Profit (loss) for the period to be appropriated9905€1.6m€1.3m▼

Appropriation of the result

Profit (loss) to be appropriated9906€18.5m€19.7m▲

Profit (loss) brought forward from the previous period14P€16.8m€18.5m▲

Social balance

Average headcount (FTE)908711.511.3▼

The notes to these accounts (10 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line	2021	2022	2023	2024	2025	Change
Turnover70	€6.1m	€5.1m	€4.5m	€5.4m	€5.4m	▲ 0.3%
Goods, raw materials, services and sundry goods60/61	€2.2m	€2.2m	€2.3m	€2.5m	€2.7m	▲ 6.0%
Remuneration, social security and pensions62	€1.2m	€1.1m	€1.2m	€1.2m	€1.2m	▼ 1.4%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630	€346,628	€211,814	€243,256	€204,740	€217,122	▲ 6.0%
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4	-€221	-€1,105	€586	€445	-€1,964	▼ 541%
Provisions for liabilities and charges: additions (uses and reversals)635/8	€125,000	€127,000	€129,000	-	-	-
Other operating charges640/8	€14,556	€9,665	€21,599	€15,732	€15,398	▼ 2.1%
Gross operating margin9900	€3.9m	€3.0m	€2.2m	€2.8m	€2.7m	▼ 4.8%
Operating profit (loss)9901	€2.2m	€1.5m	€647,713	€1.4m	€1.3m	▼ 9.3%
Financial income75/76B	€54,363	€155,765	€748,624	€857,827	€575,605	▼ 32.9%
Recurring financial income75	€54,363	€155,765	€748,624	€857,827	€575,605	▼ 32.9%
Financial charges65/66B	€2,582	€9,040	€29,010	€90,466	€100,539	▲ 11.1%
Recurring financial charges65	€2,582	€9,040	€29,010	€90,466	€100,539	▲ 11.1%
Profit (loss) for the period before taxes9903	€2.3m	€1.6m	€1.4m	€2.2m	€1.7m	▼ 19.6%
Income taxes67/77	€706,361	€403,415	€398,054	€507,679	€458,608	▼ 9.7%
Profit (loss) for the period9904	€1.6m	€1.2m	€969,273	€1.6m	€1.3m	▼ 22.6%
Profit (loss) for the period to be appropriated9905	€1.6m	€1.2m	€969,273	€1.6m	€1.3m	▼ 22.6%

Line	2021	2022	2023	2024	2025	Change
Assets
Total assets20/58	€19.9m	€20.8m	€21.9m	€23.7m	€24.9m	▲ 5.1%
Fixed assets21/28	€869,818	€923,271	€808,809	€795,964	€835,211	▲ 4.9%
Intangible fixed assets21	-	€32,108	€0	€0	€24,929	-
Tangible fixed assets22/27	€833,905	€860,463	€776,939	€750,743	€767,266	▲ 2.2%
Land and buildings22	€34,823	€32,636	€36,704	€60,043	€95,937	▲ 59.8%
Plant, machinery and equipment23	€544,469	€638,967	€687,086	€576,016	€595,018	▲ 3.3%
Furniture and vehicles24	€106,154	€67,868	€53,149	€43,815	€23,651	▼ 46.0%
Leasing and similar rights25	-	-	-	-	€3,233	-
Assets under construction and advance payments27	€148,459	€120,991	€0	€70,869	€49,426	▼ 30.3%
Financial fixed assets28	€35,913	€30,700	€31,870	€45,221	€43,017	▼ 4.9%
Current assets29/58	€19.0m	€19.9m	€21.1m	€22.9m	€24.0m	▲ 5.1%
Stocks and contracts in progress3	€231,184	€290,441	€320,334	€257,920	€320,890	▲ 24.4%
Stocks30/36	€231,184	€290,441	€320,334	€257,920	€320,890	▲ 24.4%
Amounts receivable within one year40/41	€18.5m	€19.5m	€20.7m	€22.5m	€23.7m	▲ 5.3%
Trade receivables40	€502,805	€409,138	€340,498	€613,860	€588,367	▼ 4.2%
Other amounts receivable41	€18.0m	€19.1m	€20.4m	€21.9m	€23.1m	▲ 5.6%
Cash at bank and in hand54/58	€224,626	€39,727	€11,311	€2,481	€14,655	▲ 491%
Deferred charges and accrued income490/1	€54,874	€42,221	€39,181	€108,178	€17,653	▼ 83.7%
Equity and liabilities
Total equity and liabilities10/49	€19.9m	€20.8m	€21.9m	€23.7m	€24.9m	▲ 5.1%
Equity10/15	€17.2m	€18.4m	€19.4m	€21.1m	€22.3m	▲ 6.0%
Contributions10/11	€2.4m	€2.4m	€2.4m	€2.4m	€2.4m	=
Capital10	€2.0m	€2.0m	€2.0m	€2.0m	€2.0m	=
Issued capital100	€2.0m	€2.0m	€2.0m	€2.0m	€2.0m	=
Outside capital11	€391,000	€391,000	€391,000	€391,000	€391,000	=
Share premium1100/10	€391,000	€391,000	€391,000	€391,000	€391,000	=
Reserves13	€200,000	€200,000	€200,000	€200,000	€200,000	=
Non-distributable reserves130/1	€200,000	€200,000	€200,000	€200,000	€200,000	=
Legal reserve130	€200,000	€200,000	€200,000	€200,000	€200,000	=
Profit (loss) carried forward14	€14.6m	€15.9m	€16.8m	€18.5m	€19.7m	▲ 6.9%
Provisions and deferred taxes16	€1.3m	€1.4m	€1.6m	€1.6m	€1.6m	=
Provisions for liabilities and charges160/5	€1.3m	€1.4m	€1.6m	€1.6m	€1.6m	=
Environmental obligations163	€1.3m	€1.4m	€1.6m	€1.6m	€1.6m	=
Amounts payable17/49	€1.4m	€944,351	€904,697	€1.0m	€978,856	▼ 5.4%
Amounts payable within one year42/48	€1.4m	€944,351	€904,697	€1.0m	€978,856	▼ 5.4%
Trade debts44	€909,308	€524,925	€593,394	€679,748	€780,733	▲ 14.9%
Suppliers440/4	€909,308	€524,925	€593,394	€679,748	€780,733	▲ 14.9%
Taxes, remuneration and social security45	€443,302	€419,426	€311,303	€355,460	€198,123	▼ 44.3%
Taxes450/3	€275,113	€246,219	€129,941	€45,881	-	-
Remuneration and social security454/9	€168,188	€173,207	€181,363	€309,579	€198,123	▼ 36.0%

Line	2021	2022	2023	2024	2025	Change
Profit (loss) for the period9904	€1.6m	€1.2m	€969,273	€1.6m	€1.3m	▼ 22.6%
+ Depreciation and write-downs630	€346,628	€211,814	€243,256	€204,740	€217,122	▲ 6.0%
Operating cash flow (approximation)	€1.9m	€1.4m	€1.2m	€1.8m	€1.5m	▼ 19.4%
Investment in fixed assets (approximation)	-	-€265,267	-€128,795	-€191,894	-€256,370	▼ 33.6%
Change in cash	-	-€184,899	-€28,416	-€8,830	€12,173	▲ 238%

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Timeline · acts, filings and financial milestones

All 32Financial 1Gazette 21Filings 10

Next filing, fiscal year 2026, expected by 31-07-2027

2026

03-08

NBB filing Annual accounts filed

fiscal year 2025 · full schema · 3 days late

2025

22-09

State Gazette act Resignation: Xavier Defourt (director)

Appointment: Beryle Zany (director) · Mandate compensation · Power of attorney6 facts ▸

General meeting, 17-06-2025
Director resignation, Xavier Defourt (director)
Director appointment, Beryle Zany (director)
Mandate compensation, Beryle Zany
Power of attorney, Laury Dormey
Power of attorney, Thales Brussels SC/SCRL

16-07

NBB filing Annual accounts filed

fiscal year 2024 · full schema

2024

03-09

State Gazette act Reappointment: Philippe Dehaspe (director)

Appointment: Callens Vandelanotte NV (statutory auditor) · Permanent representative: Erik Snauwaert · Mandate compensation6 facts ▸

General meeting, 18-06-2024
Director reappointment, Philippe Dehaspe (director)
Mandate compensation, Philippe Dehaspe
Auditor appointment, Callens Vandelanotte NV (statutory auditor)
Permanent representative, Erik Snauwaert
Auditor remuneration, 8,100.00 EUR

02-07

NBB filing Annual accounts filed

fiscal year 2023 · full schema

2023

31-12

Financial Weakest financial yearnet €969,273 ▼21.3%

Net result drops to €969,273, the lowest in the series; recovery starts the following year.

27-09

State Gazette act Reappointment: Stéphan Mairlot (director)

Mandate compensation3 facts ▸

General meeting, 20-06-2023
Director reappointment, Stéphan Mairlot (director)
Mandate compensation, Stéphan Mairlot

21-08

NBB filing Annual accounts filed

fiscal year 2022 · full schema · 21 days late

23-02

State Gazette act Permanent representative: Michaël Focant

2 facts ▸

Board meeting, 17-11-2022
Permanent representative, Michaël Focant (permanent representative)

2022

15-11

NBB filing Annual accounts filed

fiscal year 2021 · full schema · 107 days late

22-09

State Gazette act Statutes amendment

3 facts ▸

General meeting, 12-09-2022
Statutes amendment
Statutes amendment

03-02

State Gazette act Appointment: Francois Jamar (director)

Permanent representative: Xavier Nys · Resignation: Dominic Rousselle (director) · Mandate compensation5 facts ▸

General meeting, 03-12-2021
Director appointment, Francois Jamar (director)
Mandate compensation, Francois Jamar
Permanent representative, Xavier Nys
Director resignation, Dominic Rousselle

Show earlier events

2021

23-09

State Gazette act Reappointments: KPMG Réviseurs d'Entreprises SCRL (statutory auditor) and Benoit Woessmer (director)

Permanent representative: Dominic Rousselle · Auditor emoluments · Auditor additional fees6 facts ▸

General meeting, 04-05-2021
Auditor reappointment, KPMG Réviseurs d'Entreprises SCRL (statutory auditor)
Permanent representative, Dominic Rousselle (permanent representative)
Director reappointment, Benoit Woessmer (director)
Auditor emoluments, EUR 10.660 HTVA, chaque année en tenant compte de l'évolution de l'indice santé
Auditor additional fees, frais directs contractés spécifiquement auprès de tiers relatifs aux cotisations variables sur chiffre d'affaires (y compris cotisation par mandat) versés à l'I…

10-06

NBB filing Annual accounts filed

fiscal year 2020 · full schema

03-03

State Gazette act Reappointments: Stéphan Mairlot (director) and Renaud Dehareng (director)

Resignation: Renaud Dehareng (director) · Appointment: Xavier Defourt (director) · Mandate compensation7 facts ▸

General meeting, 07-05-2019
Director reappointment, Stéphan Mairlot (director)
Director reappointment, Renaud Dehareng (director)
General meeting, 27-11-2020
Director resignation, Renaud Dehareng (director)
Director appointment, Xavier Defourt (director)
Mandate compensation, Xavier Defourt

2020

06-11

State Gazette act Statutes amendment

4 facts ▸

General meeting, 21-10-2020
Statutes amendment, Article 27
Statutes amendment
Statutes amendment

04-08

NBB filing Annual accounts filed

fiscal year 2019 · full schema · 4 days late

2019

06-08

NBB filing Annual accounts filed

fiscal year 2018 · full schema · 6 days late

2018

12-12

State Gazette act Appointment: KPMG Réviseurs d'Entreprises SCRL (statutory auditor)

Permanent representative: Dominic Rouselle · Auditor remuneration4 facts ▸

General meeting, 14-11-2018
Auditor appointment, KPMG Réviseurs d'Entreprises SCRL (statutory auditor)
Permanent representative, Dominic Rouselle
Auditor remuneration, 10.538,00 EUR HTVA, annuellement en tenant compte de l'évolution de l'indice santé

23-08

NBB filing Annual accounts filed

fiscal year 2017 · full schema · 23 days late

30-05

State Gazette act Assemblee Generale

Approval · Power of attorney3 facts ▸

General meeting, 09-03-2018
Approval, 09-03-2018
Power of attorney, THALES Avocats (Thales Brussels CVBA)

2017

24-08

NBB filing Annual accounts filed

fiscal year 2016 · full schema · 24 days late

2016

30-08

State Gazette act Reappointment: Benoit Woessmer (director)

2 facts ▸

General meeting, 08/06/2016
Director reappointment, Benoit Woessmer (director)

2015

24-12

State Gazette act Reappointment: KPMG Réviseurs d'Entreprises SCRL civile (statutory auditor)

Permanent representative: Dominic Rousselle · Auditor fees4 facts ▸

General meeting, 26-05-2015
Auditor reappointment, KPMG Réviseurs d'Entreprises SCRL civile (statutory auditor)
Permanent representative, Dominic Rousselle
Auditor fees, EUR 10.140,00, adaptés chaque année en tenant compte de l'évalution de l'indice santé

08-09

State Gazette act Reappointments: Stanislas Pauwels (director) and Philippe Dehaspe (director)

3 facts ▸

General meeting, 03-06-2014
Director reappointment, Stanislas Pauwels (director)
Director reappointment, Philippe Dehaspe (director)

01-04

State Gazette act Reappointment: KPMG Réviseurs d'Entreprises SCRL civile (statutory auditor)

Permanent representative: Dominic Rousselle · Resignation: Ernest & Young Réviseurs d'Entreprises SCRL Civile (statutory auditor) · Auditor emoluments4 facts ▸

Auditor reappointment, KPMG Réviseurs d'Entreprises SCRL civile (statutory auditor)
Permanent representative, Dominic Rousselle
Auditor resignation, Ernest & Young Réviseurs d'Entreprises SCRL Civile (statutory auditor)
Auditor emoluments, EUR 13.185,00, adaptés chaque année en tenant compte de l'évolution de l'indice santé

2013

11-12

State Gazette act Resignation: Emanuel Sensale (director)

Appointments: Renaud Dehareng (director) and Mairlot Stephan (managing director) · Reappointment: Mairlot Stephan (director)10 facts ▸

General meeting, 22-05-2013
Director resignation, Emanuel Sensale (director)
Director appointment, Renaud Dehareng (director)
Director reappointment, Mairlot Stephan (director)
Director appointment, Mairlot Stephan (managing director)
Board composition, Mairlot Stephan (managing director)
Board composition, S.Pauwels (chair of the board)
Board composition, Renaud Dehareng (director)
Board composition, Dehaspe (director)
Board composition, Woessmer (director)

2010

09-08

State Gazette act Resignations: Olivier Legrain (director) and François Labarre (director)

Appointments: Benoît Woessmer (director) and Emanuele Sensale (director) · Mandate compensation8 facts ▸

General meeting, 17-06-2010
Director resignation, Olivier Legrain (director)
Director resignation, François Labarre (director)
Director appointment, Benoît Woessmer (director)
Director appointment, Emanuele Sensale (director)
Director appointment, Emanuele Sensale (administrateur délégué à la gestion journalière)
Mandate compensation, Benoît Woessmer
Mandate compensation, Emanuele Sensale

2009

21-12

State Gazette act Appointment: Emst & Young Réviseurs d'entreprises BVCVBA (commissaire aux comptes)

2 facts ▸

General meeting, 21-08-2009
Auditor appointment, Emst & Young Réviseurs d'entreprises BVCVBA (commissaire aux comptes)

21-12

State Gazette act Resignation: Renaud Dehanreng (managing director)

Appointment: Olivier LEGRAIN (managing director) · Mandate compensation4 facts ▸

General meeting, 25-09-2009
Director resignation, Renaud Dehanreng (managing director)
Director appointment, Olivier LEGRAIN (managing director)
Mandate compensation, Olivier LEGRAIN

06-03

State Gazette act Resignation: Gauthier SAELENS (director)

Appointment: Philippe DEHASPE (director) · Mandate compensation4 facts ▸

General meeting, 20-02-2008
Director resignation, Gauthier SAELENS (director)
Director appointment, Philippe DEHASPE (director)
Mandate compensation, Philippe DEHASPE

2007

05-06

State Gazette act Resignation: Olivier Legrain (director and chair of the board)

Appointments: Philippe Van Den Avenne (director) and Renaud Dehareng (chair of the board) · Mandate compensation5 facts ▸

General meeting, 19-04-2007
Director resignation, Olivier Legrain (director and chair of the board)
Director appointment, Philippe Van Den Avenne (director)
Director appointment, Renaud Dehareng (chair of the board)
Mandate compensation, Philippe Van Den Avenne

Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.

21 of 22 acts read

About the unread acts

Of the 22 Belgian State Gazette acts we know for this company, 21 have been read. The other one has not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Directors · office · real estate

Directors

5 directors, last change in 2025

Board 5

Philippe DEHASPE

Director · since 20-02-2008

Current

Benoit Woessmer

Director · since 17-06-2010

Current

Stéphan Mairlot

Director · since 22-05-2013

Current

Francois Jamar

Director · since 03-12-2021

Current

Beryle Zany

Director · since 17-06-2025

Current

3 not recently confirmed

Still in office according to the acts, but no act of the last six years confirms the mandate. It has often ended since, in an act we have not read.

Philippe Van Den Avenne

Director · since 19-04-2007

Not recently confirmed

Emanuele Sensale

Director · since 17-06-2010

Not recently confirmed

Stanislas Pauwels

Director

Not recently confirmed

Day-to-day management 2

Emanuele Sensale

Administrateur délégué à la gestion journalière · since 17-06-2010

Not recently confirmed

Stéphan Mairlot

Managing director · since 01-01-2013

Not recently confirmed

Statutory auditor 1

NV Callens Vandelanotte

Statutory auditor · since 18-06-2024 · perm. rep.: Erik Snauwaert

Current

Derived from published Gazette acts. The CBE keeps the official list of function holders; we do not read it, so the two can differ. See the function holders in the CBE →

Not every act has been read: a resignation may be missing here

1 of this company's 22 Belgian State Gazette acts has not been read yet. Appointments and resignations recorded in them are missing above: a director who resigned there may therefore still show here as sitting. The acts are in the Timeline.

Location & real-estate footprint

Registered office, Sint-Lambrechts-Woluwe · 1 establishment unit since 2003

seat establishment The establishment unit on the map

Ground area

5.0 ha

Parcel 21018B0078/00R002, Brussels. Linked by address, not a title deed.

97 companies at this address See who is registered here

1 establishment unit

Hippokrateslaan 10, 1200 Sint-Lambrechts-Woluwe

Manufacture of basic pharmaceutical products and pharmaceutical preparations

since 20032.123.431.255

1 parcel

Brussels 1 (100%)

Parcel (capakey)	Region	Area	Buildings	Height / fl.
21018B0078/00R002	Brussels	5.0 ha	-	-

Linked by address, not proof of ownership

Good to know

1 of 1 parcel with an exact address match; the rest are indicative.

Linked through address data, this is not proof of ownership.

Mandate history

19 people since 2007, 9 in office

All 19 In office 9 Ended 10

Board
Day-to-day management
Statutory auditor
not recently confirmed
began earlier

Mandates per person, with start and end dates
Name	Functions and periods
Philippe DEHASPE	Director, from 20-02-2008 to date
Benoit Woessmer	Director, from 17-06-2010 to date
Stéphan Mairlot	Managing director, from 01-01-2013 not ended, last confirmed 11-12-2013 Director, already before 22-05-2013 to date
Francois Jamar	Director, from 03-12-2021 to date
Beryle Zany	Director, from 17-06-2025 to date
NV Callens Vandelanotte	Statutory auditor, from 18-06-2024 to date
Philippe Van Den Avenne	Director, from 19-04-2007 not ended, last confirmed 05-06-2007
Emanuele Sensale	Director, from 17-06-2010 not ended, last confirmed 09-08-2010 Administrateur délégué à la gestion journalière, from 17-06-2010 not ended, last confirmed 09-08-2010
Stanislas Pauwels	Director, already before 08-09-2015 not ended, last confirmed 08-09-2015
Xavier Defourt	Director, from 27-11-2020 to 17-06-2025
KPMG Réviseurs d'Entreprises SCRL	Statutory auditor, from 26-05-2015 to 18-06-2024
Dominic Rousselle	Board, until 03-12-2021
Renaud Dehareng	Chair of the board, from 19-04-2007 ended, last mentioned 05-06-2007 Director, from 22-05-2013 to 27-11-2020
Emst & Young Réviseurs d'entreprises BVCVBA	Commissaire aux comptes, from 21-08-2009 to 26-05-2015
Emanuel Sensale	Director, until 31-12-2012
François Labarre	Director, until 17-06-2010
Olivier LEGRAIN	Director and chair of the board, until 19-04-2007 Managing director, from 25-09-2009 ended, last mentioned 21-12-2009 Director, until 17-06-2010
Renaud Dehanreng	Managing director, until 25-09-2009
Gauthier SAELENS	Director, until 20-02-2008

Show all 19 people Show the first 12See the board, name and seat on a given date →

Structure & network

Owners and holdings

1 owner

Chain of control

CURIUM BIDCO S.À R.L.LU 100%
Curium International 75%
BETAPLUS PHARMA

Highest known parent: CURIUM BIDCO S.À R.L. (Luxembourg). The sources do not say who stands above it.

Owners 1

Curium Internationalparent

Sourceaccounts Curium International 2025

75%

Holdings 0

No holding stated in the accounts, acts or LEI register we read.

According to the annual accounts of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.

Connections & network

15 connected companies

Depth

Shared directors

This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, scroll to zoom.

Linked via shared directors

CENTRE CHAPELLE-AUX-CHAMPS

via Philippe DEHASPE · Director

→

Cliniques universitaires Saint-Luc

via Philippe DEHASPE · Director

→

Saint-Luc Patrimoine

via Philippe DEHASPE · Director

→

Service de Santé mentale @Le Méridien@

via Philippe DEHASPE · Director

→

Show 11 more companies with a shared director

Service Santé mentale Le Chien Vert

via Philippe DEHASPE · Director

→

Services de Santé Mentale de l'UCL à Bruxelles

via Philippe DEHASPE · Director

→

Valisana

via Philippe DEHASPE · Director

→

ASBL ENTRAIDE FRATERNELLE JOLIMONT

via Philippe DEHASPE · Director

former→

CREDE

via Philippe DEHASPE · Director

former→

EPSYLON

via Philippe DEHASPE · Director

former→

EPSYMMO

via Philippe DEHASPE · Director

former→

Fondation Saint - Luc

via Philippe DEHASPE · Administrateur du groupe b

former→

Gezondheidsinstellingen Brussel Bruxelles Institutions de Santé

via Philippe DEHASPE · Director

former→

LE BOSQUET

via Philippe DEHASPE · Director

former→

Le Roseau

via Philippe DEHASPE · Administrateur et membre de l'assemblée générale

former→

Similar companies · same sector, comparable size

Prothya Biosolutions Belgium

Hoeilaart · Eq €36.5m

BIO MINERALS

BE 0451.906.964

Destelbergen · Eq €13.5m

SHANT BIOTECH

BE 0680.795.389

Tubize · Eq €10.4m

Of 148 companies in sector 21100 we hold annual accounts for 108. 24 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Identification & contact

Identification

Legal formPublic limited company

Founded16-12-2002

Fiscal year end31-12

Abbreviation FR betaplus

Activities, NACEBEL 2025

21100Manufacture of basic pharmaceutical products and pharmaceutical preparations

21201Manufacture of basic pharmaceutical products and pharmaceutical preparations

21209Manufacture of basic pharmaceutical products and pharmaceutical preparations

E-invoicing

Reachable via Peppol

Peppol ID 0208:0479037369

Registered 31-03-2026

Scores and ratios are computed by Checked and are not a credit decision.